Literature DB >> 29341237

The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.

Daniel F B Wright1, Nicola Dalbeth2, Amanda J Phipps-Green3, Tony R Merriman3, Murray L Barclay4,5, Jill Drake4, Paul Tan2, Anne Horne2, Lisa K Stamp4.   

Abstract

AIM: This research aims to evaluate the predictive performance of a published allopurinol dosing tool.
METHODS: Allopurinol dose predictions were compared to the actual dose required to achieve serum urate (SU) <0.36 mmol l-1 using mean prediction error. The influence of patient factors on dose predictions was explored using multilinear regression.
RESULTS: Allopurinol doses were overpredicted by the dosing tool; however, this was minimal in patients without diuretic therapy (MPE 63 mg day-1 , 95% CI 40-87) compared to those receiving diuretics (MPE 295 mg day-1 , 95% CI 260-330, P < 0.0001). ABCG2 genotype (rs2231142, G>T) had an important impact on the dose predictions (MPE 201, 107, 15 mg day-1 for GG, GT and TT, respectively, P < 0.0001). Diuretic use and ABCG2 genotype explained 53% of the variability in prediction error (R2  = 0.53, P = 0.0004).
CONCLUSIONS: The dosing tool produced acceptable maintenance dose predictions for patients not taking diuretics. Inclusion of ABCG2 genotype and a revised adjustment for diuretics would further improve the performance of the dosing tool.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  ABCG2; allopurinol; diuretics; genotype; gout; urate

Mesh:

Substances:

Year:  2018        PMID: 29341237      PMCID: PMC5903228          DOI: 10.1111/bcp.13516

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

2.  Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.

Authors:  Diluk R W Kannangara; Amanda J Phipps-Green; Nicola Dalbeth; Lisa K Stamp; Kenneth M Williams; Garry G Graham; Richard O Day; Tony R Merriman
Journal:  Ann Rheum Dis       Date:  2015-12-01       Impact factor: 19.103

Review 3.  The genetic basis of hyperuricaemia and gout.

Authors:  Tony R Merriman; Nicola Dalbeth
Journal:  Joint Bone Spine       Date:  2010-05-15       Impact factor: 4.929

4.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

5.  Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

Authors:  Nicola Dalbeth; Sunil Kumar; Lisa Stamp; Peter Gow
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

6.  Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.

Authors:  Lisa K Stamp; Peter T Chapman; Murray Barclay; Anne Horne; Christopher Frampton; Paul Tan; Jill Drake; Nicola Dalbeth
Journal:  Ann Rheum Dis       Date:  2017-08-22       Impact factor: 19.103

7.  Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.

Authors:  C C Wen; S W Yee; X Liang; T J Hoffmann; M N Kvale; Y Banda; E Jorgenson; C Schaefer; N Risch; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2015-04-06       Impact factor: 6.875

8.  The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.

Authors:  Daniel F B Wright; Nicola Dalbeth; Amanda J Phipps-Green; Tony R Merriman; Murray L Barclay; Jill Drake; Paul Tan; Anne Horne; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

9.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

Review 10.  2016 updated EULAR evidence-based recommendations for the management of gout.

Authors:  P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin
Journal:  Ann Rheum Dis       Date:  2016-07-25       Impact factor: 19.103

View more
  3 in total

1.  The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.

Authors:  Daniel F B Wright; Nicola Dalbeth; Amanda J Phipps-Green; Tony R Merriman; Murray L Barclay; Jill Drake; Paul Tan; Anne Horne; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

Review 2.  Role of Genetic Variations in the Hepatic Handling of Drugs.

Authors:  Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero
Journal:  Int J Mol Sci       Date:  2020-04-20       Impact factor: 5.923

3.  Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.

Authors:  Lisa K Stamp; Peter T Chapman; Murray Barclay; Anne Horne; Christopher Frampton; Tony R Merriman; Daniel F B Wright; Jill Drake; Nicola Dalbeth
Journal:  Clin Transl Sci       Date:  2019-09-03       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.